The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPlant Health Regulatory News (PHC)

Share Price Information for Plant Health (PHC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.82
Bid: 3.70
Ask: 3.94
Change: 0.01 (0.26%)
Spread: 0.24 (6.486%)
Open: 3.81
High: 0.00
Low: 0.00
Prev. Close: 3.81
PHC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Brazil approves TEIKKOâ„¢

2 Jan 2024 07:00

RNS Number : 2675Y
Plant Health Care PLC
02 January 2024
 

2 January 2024

 

Plant Health Care plc

 ("Plant Health Care" or the "Company")

 

Brazil approves TEIKKO? (PHC68949) to Control Nematodes in Soybeans

  

Plant Health Care® (AIM.PHC.L), a leading provider of peptides used by growers to improve crop production and quality within global agriculture markets, is pleased to announce that its nematicide, TEIKKO, has received federal approval in Brazil in time for commercial launch for the 2024/25 soybean growing season. 

 

Highlights

- TEIKKO is an entirely novel peptide product which offers farmers good control of nematode pests, without resorting to conventional agrochemicals;

- Brazilian farmers spent more than $200m on nematode control in the most recent season; and

- The Company is in discussion with potential distributors for launch of TEIKKO during 2024.

 

TEIKKO is a novel product, from the Company's PREtec peptide platform, that amplifies a plant's natural defense pathways to provide protection against plant parasitic nematodes which damage plant roots and limit crop yield. TEIKKO is now approved as a seed treatment for the control of root-lesion nematode (Pratylenchus brachyurus) in soybean. Research carried out during the 2021/22 and 2022/23 soybean crop seasons showed that TEIKKO gave similar or superior performance to standard agrochemical treatments. TEIKKO offers farmers the opportunity to avoid use of toxic agrochemicals, without sacrificing performance. Compared with alternative biological products, it brings benefits such as three-year shelf-life and no special requirements for storing, allowing flexibility on distribution to the farmers, low rates for easy industrial seed treatment, no interference or incompatibility with other traditional seed treatments, such as fungicides and insecticides, and reliable performance under different environmental conditions, such as drought or humidity. For the 2023/24 season, the soybean harvested area in Brazil is forecast to be 45 million hectares.

 

According to the latest research published by Kynetec, Brazilian growers spent $215 million on soybean nematode control for the 2022/23 season, which reflects an annualized growth rate of 55% over the last six years. Additional crops and nematode species will be added to the TEIKKO product label in the future, further expanding its potential use.

 

Plant Health Care is progressing discussions with several distribution partners who will launch TEIKKO in 2024, for use for the 2024/25 soybean growing season.

 

TEIKKO is based on the Company's innovative PREtec technology platform. Derived from natural proteins, PREtec is an environmentally friendly technology which stimulates plant defense and pathogen resistance mechanisms within plants, resulting in improved crop growth and quality along with the ability to withstand a variety of abiotic stresses. 

 

Jeff Tweedy, CEO of Plant Health Care, said: ?TEIKKO will help Brazilian farmers sustainably produce their soybean crops and supports the Company's vision to be a leading global provider of alternatives to conventional agrochemicals. Unlike TEIKKO, current soil fumigants and other chemical nematicides are known to have damaging off-target effects. TEIKKO is an environmentally friendly biological alternative that performs as well as or better than those older technologies and we expect to see rapid adoption amongst Brazilian farmers. We are excited about the developing plans to launch TEIKKO in 2024, with strong growth thereafter."

 

# # #

 

 

For further information, please contact: 

Plant Health Care plc Jeff Tweedy, CEO

 

Tel: +1 919 926 1600

Cavendish Capital Markets Limited - Nomad & Broker Neil McDonald / Pete Lynch

Tel: +44 (0) 131 220 9771

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes, and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REATMBITMTIJBFJ
Date   Source Headline
22nd Apr 20247:00 amRNSApproval of Harpinαβ in Belgium
16th Apr 20247:00 amRNSPlant Health Care--China Distribution with AMVAC
4th Apr 20247:00 amRNSApproval of PHC68949 in Mexico
4th Mar 20241:55 pmRNSHolding(s) in Company
24th Jan 20244:27 pmRNSHolding(s) in Company
2nd Jan 20247:00 amRNSBrazil approves TEIKKOâ„¢
20th Dec 20237:00 amRNSBoard Changes and Grant of Options
19th Dec 20233:34 pmRNSHolding(s) in Company
30th Nov 20231:45 pmRNSHolding(s) in Company
28th Nov 20233:16 pmRNSHolding(s) in Company
27th Nov 20234:03 pmRNSHolding(s) in Company
27th Nov 20231:27 pmRNSHolding(s) in Company
24th Nov 20234:19 pmRNSDirector/PDMR Shareholding
24th Nov 202310:57 amRNSDirector/PDMR Shareholding
23rd Nov 20232:31 pmRNSHolding(s) in Company
22nd Nov 20237:00 amRNSTrading Update
31st Oct 20237:00 amRNSChange of Adviser
20th Oct 20237:00 amRNSHolding(s) in Company
3rd Oct 20236:28 pmRNSPlant Health Care PREtec Product with Agrii UK
28th Sep 20237:00 amRNSNew PREtec Products Announced
27th Sep 20237:00 amRNSUnaudited Interim Results
25th Sep 20237:00 amRNSPREtec Products Submitted for Regulatory Approval
31st Aug 20237:00 amRNSNotice of Results & Investor Presentation
18th Aug 20237:00 amRNSNew Product Regulatory Approval In Brazil
1st Aug 20237:00 amRNSApproval for Sale of Harpin aß Granted in Poland
24th Jul 20237:00 amRNSGrant of Options
12th Jul 202312:27 pmRNSHolding(s) in Company
30th Jun 20235:07 pmRNSNotification of Major Holdings
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.